Repros Therapeutics Inc. Reports 6 Month Bone Mineral Density Data From Ongoing Study ZA-303
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
THE WOODLANDS, Texas, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported interim 6 month results from the first 150 subjects enrolled into the ongoing one year placebo controlled study to assess the impact of Androxal treatment of secondary hypogonadal men and its effect on bone mineral density. There is no evidence of a deleterious effect of Androxal on bone health and some evidence of improved bone mineral density.
Help employers find you! Check out all the jobs and post your resume.
THE WOODLANDS, Texas, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported interim 6 month results from the first 150 subjects enrolled into the ongoing one year placebo controlled study to assess the impact of Androxal treatment of secondary hypogonadal men and its effect on bone mineral density. There is no evidence of a deleterious effect of Androxal on bone health and some evidence of improved bone mineral density.
Help employers find you! Check out all the jobs and post your resume.